Novel method and agent for treating, diagnosing and detecting diabetes and complications
AssigneeBiozipcode, Inc.
InventorsHideto Kojima, Tomoya Terashima, Miwako Katagi
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a therapy for diabetes that targets abnormal stem cells by HDAC inhibitors in combination with stem cell migration. In one embodiment, the present disclosure provides a therapy for diabetes and/or diabetes-related diseases and disorders and/or symptoms that targets abnormal stem cells by HDAC inhibitors in combination with stem cell migration. In one embodiment, the present disclosure provides a therapy for diabetes and/or diabetes-related diseases and disorders and/or symptoms that targets abnormal stem cells by HDAC inhibitors in combination with stem cell migration, in a subject in which abnormal stem cells have been detected.
Claims23
A composition for treating and/or preventing diabetes mellitus, and/or a disease, disorder and/or symptom associated with diabetes mellitus, comprising a suppressing agent for an abnormal hematopoietic stem cell (HSC), wherein the suppressing agent comprises a histone deacetylase (HDAC) inhibitor, and the composition is administered in combination with a stem cell migration agent.
A medicament for treating and/or preventing diabetes mellitus, and/or a disease, disorder and/or symptom associated with diabetes mellitus, the medicament comprising a combination of a suppressing agent for an abnormal hematopoietic stem cell (HSC) containing an HDAC inhibitor and a stem cell migration agent.
A composition for treating and/or preventing diabetes mellitus, and/or a disease, disorder and/or symptom associated with diabetes mellitus, the composition comprising a stem cell migration agent, characterized in that the stem cell migration agent is administered in combination with a suppressing agent for an abnormal hematopoietic stem cell (HSC) containing an HDAC inhibitor.
A composition for diagnosing diabetes mellitus, and/or a disease, disorder and/or symptom associated with diabetes mellitus, or a risk thereof, comprising an abnormal hematopoietic stem cell (HSC) detection agent comprising an HDAC detection agent.
A composition for selecting a treatment for treating and/or preventing diabetes mellitus, and/or a disease, disorder and/or symptom associated with diabetes mellitus, the composition comprising an agent that detects a migration and/or residual state of an abnormal hematopoietic stem cell (HSC) containing an HDAC detection agent.
A method for treating and/or preventing diabetes mellitus, or a disease, disorder and/or symptom associated with diabetes mellitus in a subject, comprising administering an effective amount of an agent that reduces or eliminates an abnormal hematopoietic stem cell (HSC) containing an HDAC inhibitor and a stem cell migration agent to the subject.
A method for diagnosing diabetes mellitus or diabetes mellitus, and/or a disease, disorder and/or symptom associated with diabetes mellitus, or a risk thereof in a subject, comprising detecting an abnormal hematopoietic stem cell (HSC) in the subject based on an HDAC gene or protein expression.
A method for using a migration and/or residual state of an abnormal hematopoietic stem cell (HSC) as an indicator of treatment for treating and/or preventing diabetes mellitus or diabetes mellitus, and/or a disease, disorder and/or symptom associated with diabetes mellitus in a subject, comprising detecting the migration and/or residual state of the abnormal hematopoietic stem cell (HSC) in the subject based on an HDAC gene or protein expression.
Dependencies are inferred from the claim text.